Related Experiment Video
Updated: Jun 10, 2026
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis
Man Li1, Baogang Zhang, Baocun Sun
1Department of Pathology, Tianjin Cancer Institute and Hospital, Tianjin Medical University, Tianjin, People's Republic of China.
Journal of Experimental & Clinical Cancer Research : CR
|August 13, 2010
Summary
Vimentin is a potential biomarker for predicting melanoma metastasis. Its elevated expression in primary tumors correlates with hematogenous spread, offering a new diagnostic tool for high-risk patients.
Area of Science:
- Oncology
- Proteomics
- Cancer Metastasis Research
Background:
- Malignant melanoma (MM) incidence is rising globally.
- Melanoma metastasis remains a significant clinical challenge.
- Identifying metastasis biomarkers is crucial for effective treatment.
Purpose of the Study:
- To identify protein biomarkers associated with melanoma lung metastasis.
- To investigate the role of differentially expressed proteins in melanoma progression.
- To validate potential biomarkers in clinical samples.
Main Methods:
- Created spontaneous lung metastatic mouse models using B16F10 melanoma cells.
- Analyzed differential protein expression using 2D-DIGE and MALDI-TOF/MS.
- Validated protein expression and clinical significance via Western blotting and immunohistochemistry.
Main Results:
- Identified 30 differentially expressed proteins, including vimentin, actin, and glycolytic enzymes.
- Vimentin was significantly upregulated in metastatic melanoma tissues.
- Vimentin overexpression in primary tumors correlated with hematogenous metastasis, not lymph node metastasis.
Conclusions:
- Aberrant vimentin expression in melanoma tissues may indicate a high risk of hematogenous metastasis.
- Vimentin shows potential as a novel diagnostic and prognostic biomarker for melanoma metastasis.
- TNM staging is an independent indicator of poor prognosis in melanoma patients.
